ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Explore the role of ctHPVDNA kinetics during diagnosis and follow-up of HPV OPSCC.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe primary objective is to determine the positive predictive value (PPV) of ctHPVDNA for diagnosis and recurrence. Secondary objectives include measuring the lead time between ctHPVDNA positivity and pathological recurrence.
methodsddPCR reactions were prepared with 2× ddPCR Supermix for Probes (No dUTP) (Bio-Rad) and assay-specific primers/probes targeting the E6/E7 region of HPV16, HPV33, and HPV35. Patients were included in the diagnosis cohort if they had at least one ctHPVDNA measurement obtained prior to the initiation of primary treatment. Patients were assigned to the surveillance cohort if they had at least one ctHPVDNA test performed following completion of definitive or salvage therapy.
resultsAt diagnosis test revealed in 167 patients a PPV of 98,5% (95% CI, 94,6%-99,8%) and NPP of 97,1% (95% CI, 85,1%-99,9%). At follow up, ctHPVDNA testing demonstrated in 165 patients PPV of 96,9% (95% CI, 84,3%-99,4% [31 of 32 tests]), and NPV of 100% (95% CI, 98,9%-100% [351 of 351 tests]). There was a median lead time of positive test to event (recurrence day) of 44 days (range, 0-343 days) and mean (SD) of 143 (167,8) days. When we consider only the 11 patients enrolled at the time of the first diagnosis and followed with serial blood sampling, the median lead time was 331 days (range, 23-393 days) and mean (SD) of 233 (156,7) days.
conclusionctHPVDNA represents a promising dynamic biomarker for diagnosis and Follow-up. Incorporation of ctHPVDNA kinetics into follow-up protocols may reduce reliance on frequent imaging, enabling a targeted follow-up strategy and allowing earlier detection of recurrence.
Indexed as
Identifiers
41735552What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.